Woodline Partners »

Aligos Therapeutics shares owned by Woodline Partners

Quarter-by-quarter ownership of Aligos Therapeutics shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Aligos Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aligos Therapeutics held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aligos Therapeutics by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $797k 92k 8.66

More positions owned by Woodline Partners

Meta Platforms Cl A (META)
Gilead Sciences (GILD)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Vaxcyte (PCVX)
Asml Holding N V N Y Registry Shs (ASML)
Nuvalent Inc-a (NUVL)
Permian Resources Corp Class A Com (PR)
Encana Corporation (OVV)
Keysight Technologies (KEYS)
Danaher Corporation (DHR)
Aon Shs Cl A (AON)
Stmicroelectronics N V Ny Registry (STM)
Regeneron Pharmaceuticals (REGN)
EQT Corporation (EQT)

View all positions for Woodline Partners

Top funds holding Aligos Therapeutics

Woodline Partners
Baker Bros. Advisors
Hillhouse Capital Advisors
Acadian Asset Management
Geode Capital Management
Renaissance Technologies
Charles Schwab Investment Management
BlackRock
Bank of America Corporation
CWM
Advisor Group Holdings
AlphaMark Advisors
Jpmorgan Chase & Co
Zrc Wealth Management
Bnp Paribas Arbitrage, Snc

View all funds holding Aligos Therapeutics